UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005389
Receipt number R000006398
Scientific Title Phase I/ II study of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Date of disclosure of the study information 2011/04/06
Last modified on 2011/04/06 16:25:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase I/ II study of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Acronym

S-1 and cisplatin with concurrent radiotherapy for NSCLC.

Scientific Title

Phase I/ II study of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Scientific Title:Acronym

S-1 and cisplatin with concurrent radiotherapy for NSCLC.

Region

Japan


Condition

Condition

Lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the feasibility and efficacy of S-1 and cisplatin with concurrent thoracic radiation for unresectable stage III non-small-cell lung cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase I,II


Assessment

Primary outcomes

2-year survival rate

Key secondary outcomes

objective response rate,overall survival,progression-free survival,toxicity


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Level 1;
CDDP 60 mg/m2, day 8
S-1 80 mg/m2 days 1-14 every 3weeks
Level 2;
CDDP 60 mg/m2, day 8
S-1 80 mg/m2 days 1-21 every 4weeks

Thoracic radiation 60Gy/30fr

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

Eligibility criteria were: histological or cytological diagnosis of unresectable stage III NSCLC; no prior chemotherapy; measurable lesions; PS (ECOG) 0-1; adequate hematology and biochemistry parameters; and informed consent.

Key exclusion criteria

Exclusion criteria were:active concomitant malignancy; active pulmonary fibrosis or interstitial pneumonia ; watery diarrhea; serious complications; pregnancy; psychotic disorder; and drug allergy.

Target sample size

45


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kiyotaka Yoh

Organization

National Cancer Center Hospital East

Division name

Division of Thoracic Oncology

Zip code


Address

6-5-1,Kashiwanoha,Kashiwa-shi,Chiba-ken,277-8577

TEL

04-7133-1111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Tetsuhiko Taira

Organization

National Cancer Center Hospital East

Division name

Division of Thoracic Oncology

Zip code


Address

6-5-1,Kashiwanoha,Kashiwa-shi,Chiba-ken,277-8577

TEL


Homepage URL


Email



Sponsor or person

Institute

National Cancer Center Hospital East

Institute

Department

Personal name



Funding Source

Organization

National Cancer Center Hospital East

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立がん研究センター東病院


Other administrative information

Date of disclosure of the study information

2011 Year 04 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2005 Year 07 Month 28 Day

Date of IRB


Anticipated trial start date

2005 Year 08 Month 01 Day

Last follow-up date

2012 Year 08 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 04 Month 06 Day

Last modified on

2011 Year 04 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006398


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name